logo-loader
viewArix Bioscience PLC

Arix Bioscience reveals one of its portfolio companies, Imara Inc. has applied to list on Nasdaq

Imara is a clinical-stage biotechnology company focused on developing new medicines to treat patients suffering from rare inherited genetic disorders of haemoglobin

Nasdaq sign
All shares to be sold in the offering will be offered by Imara

Arix Bioscience PLC (LON:ARIX), the global venture capital company focused on investing in and building breakthrough biotech companies, has revealed that one of its portfolio companies, Imara Inc. has applied to list on the Nasdaq Global Market.

Arix noted that Imara has filed a registration statement on Form S-1 with the US Securities and Exchange Commission for a proposed initial public offering in shares of its common stock.

READ: Arix Bioscience investee company Autolus publishes encouraging additional data from blood cancer drug study

All shares to be sold in the offering will be offered by Imara.

Imara is a clinical-stage biotechnology company focused on developing new medicines to treat patients suffering from rare inherited genetic disorders of haemoglobin.

The group's lead programme is in Phase 2 clinical development for sickle cell disease  - a rare, genetic blood disease that leads to a reduction of healthy red blood cells, blocked blood vessels, and a multitude of pathologies.

The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering, the statement said.

It added that a further announcement will be made in due course.

Quick facts: Arix Bioscience PLC

Price: 60 GBX

LSE:ARIX
Market: LSE
Market Cap: £81.33 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19

2 min read